Bispecific Antibodies as Novel Bioconjugates
- 20 October 1998
- journal article
- review article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 9 (6) , 635-644
- https://doi.org/10.1021/bc980044l
Abstract
Bispecific antibodies are unique macromolecular heterobifunctional cross-linkers with two different binding specificities within a single molecule. As ideal bioconjugates, they can specifically glue any two different molecules together without the need for chemical conjugation. With this unique feature, they have immense potential in biological and immunological fields. Their applications range from immunohistochemistry, immunoassays, radioimmunodiagnosis, radioimmunotherapy, and immunotherapy. Recently, a new second generation of bispecific molecules, bispecific single chain Fv and diabodies, has been produced by DNA recombinant technology. They can be considered as the ultimate magic bullets for in vivo applications. They may theoretically improve tumor or pathogen targeting and minimize side effects, eventually replacing the full-length bispecific antibodies. Emphasizing on developmental methodology and clinical applications of bispecific antibodies, this review gives a bird's-eye view of these unique bioconjugates.Keywords
This publication has 45 references indexed in Scilit:
- Clinical Trials of Bispecific Antibody MDX-210 in Women with Advanced Breast or Ovarian Cancer that Overexpresses HER-2/neuJournal of Hematotherapy, 1995
- Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3European Journal Of Cancer, 1994
- Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal‐cell carcinoma xenografts: Relative effects of size and affinityInternational Journal of Cancer, 1991
- T cell targeting in cancer therapyCancer Immunology, Immunotherapy, 1991
- Bifunctional antibodies: concept, production and applicationsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1990
- T cell activation by a bispecific anti-CD3/anti-major histocompatibility complex class I antibodyEuropean Journal of Immunology, 1990
- Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell.The Journal of Experimental Medicine, 1989
- Bispecific Antibody-Producing Hybrid Hybridoma and Its Use in One-Step Immunoassays for Human LymphotoxinHybridoma, 1989
- Redirecting the Cellular Immune ResponseInternational Reviews of Immunology, 1989
- Fusion of Two Immunoglobulin-producing Myeloma CellsNature, 1973